Business

Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs

Financial Post · September 14, 2026 at 5:52 p.m.

BEXLUTRY is the first radioligand equivalent for the treatment of GEP-NETs in adults and the first radioligand therapy from Curium™ approved by the FDA BOSTON, Sept.

14, 2026 (GLOBE NEWSWIRE) — Curium™ announced today th

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs

More from Financial Post

Marcus & Millichap and Brown & Brown Expand Preferred Partner Relationship into Canada

Cavvy Energy to Hold Conference Call and Webcast to Discuss Third Quarter 2026 Results and Announces Participation at Schachter Catch the Energy Conference

Lithium Argentina to Release Third Quarter 2026 Results on November 10, 2026

September 2026 Quarter Production Update

More in Business

Marcus & Millichap and Brown & Brown Expand Preferred Partner Relationship into Canada

Cavvy Energy to Hold Conference Call and Webcast to Discuss Third Quarter 2026 Results and Announces Participation at Schachter Catch the Energy Conference

Lithium Argentina to Release Third Quarter 2026 Results on November 10, 2026

September 2026 Quarter Production Update

Parex Resources Announces Production Update and Timing of Q3 2026 Results

Aritzia raises 2027 outlook as Q2 revenue up 44 per cent to $1.17 billion